New Delhi

Glenmark Pharmaceuticals on Friday said its US-based arm is preparing to launch a generic version of Sodium Phosphates Injection in the American market.

The Mumbai-headquartered drugmaker said the product is therapeutically equivalent to the reference listed drug of Hospira Inc.

According to the company’s regulatory filing, distribution of the injection in the United States is expected to begin in April 2026.

As per sales data from IQVIA, Sodium Phosphates Injection USP single-dose vials recorded annual sales of about USD 66.8 million in the 12-month period ending December 2025.

READ MORE: Anika’s battle for life: Muslims extend a helping hand

Shares of Glenmark Pharmaceuticals were trading 0.82 per cent higher at Rs 2,144.50 apiece on the BSE.